BioPharma Credit Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Other Revenue	157.75	150.03	135.74	218.17	103.88	Upgrade
Revenue	157.75	150.03	135.74	218.17	103.88	Upgrade
Revenue Growth (YoY)	5.14%	10.53%	-37.78%	110.02%	-5.58%	Upgrade
Gross Profit	157.75	150.03	135.74	218.17	103.88	Upgrade
Selling, General & Admin	28.03	27.72	27.28	35.79	18.95	Upgrade
Other Operating Expenses	-0.14	0.13	0	0.04	-0.05	Upgrade
Operating Expenses	27.9	27.85	27.28	35.83	18.9	Upgrade
Operating Income	129.85	122.18	108.46	182.34	84.98	Upgrade
Currency Exchange Gain (Loss)	0.04	-0	-0.01	-0.03	-0.02	Upgrade
Pretax Income	129.89	122.18	108.45	182.31	84.96	Upgrade
Net Income	129.89	122.18	108.45	182.31	84.96	Upgrade
Net Income to Common	129.89	122.18	108.45	182.31	84.96	Upgrade
Net Income Growth	6.31%	12.66%	-40.51%	114.59%	-4.69%	Upgrade
Shares Outstanding (Basic)	1,140	1,222	1,309	1,364	1,374	Upgrade
Shares Outstanding (Diluted)	1,140	1,222	1,309	1,364	1,374	Upgrade
Shares Change (YoY)	-6.77%	-6.65%	-4.00%	-0.72%	-0.00%	Upgrade
EPS (Basic)	0.11	0.10	0.08	0.13	0.06	Upgrade
EPS (Diluted)	0.11	0.10	0.08	0.13	0.06	Upgrade
EPS Growth	14.03%	20.68%	-38.03%	116.14%	-4.68%	Upgrade
Dividend Per Share	0.070	0.070	0.070	0.070	0.070	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	82.31%	81.44%	79.90%	83.58%	81.80%	Upgrade
Profit Margin	82.34%	81.44%	79.90%	83.56%	81.79%	Upgrade
EBIT	129.85	122.18	108.46	182.34	84.98	Upgrade
EBIT Margin	82.31%	81.44%	79.90%	83.58%	81.80%	Upgrade
Revenue as Reported	157.78	150.03	135.73	218.14	103.86	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.